search
Back to results

Vessel Deformations and Restenosis After Stenting of the Popliteal Artery (FIRESTEP)

Primary Purpose

Peripheral Arterial Disease, Popliteal Artery Stenosis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Interwoven stent
Laser-cut stent
Sponsored by
Kantonsspital Aarau
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease

Eligibility Criteria

21 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent prior to any study procedure,
  • Presence of PAD (2 - 3 Rutherford-Becker class),
  • Atherosclerotic de-novo lesion (stenosis >70% or occlusion) of the distal part of the superficial femoral artery and/or any part of the popliteal artery,
  • Target lesion-length: 4cm to 12cm,
  • Target vessel diameter: 5mm to 7mm,
  • Guidewire must cross target lesion and located intraluminally before randomization,
  • At least one (1) patent below-the knee artery (=with no stenosis >50%),
  • Possibility to treat the target lesion with one (1) study stent
  • Interventions in TASC A and B lesions to restore adequate blood flow, in the same index procedure, are allowed. This intervention must be prior to the treatment of the study lesion(s) and successful.

Exclusion Criteria:

  • Pregnancy,
  • Angiographic evidence of thrombus within the target lesion,
  • Patients with acute critical limb ischemia (Rutherford-Becker class 4-6),
  • Restenosis of the target lesion,
  • Non-atherosclerotic obstructions of the target lesion,
  • Aneurysm of the target lesion,
  • Renal failure, defined as GFR, <40 mL/min/1.73m2,
  • Patient's inability to follow the study procedures e.g. psychological disorders, dementia, etc.,
  • Previous enrolment into an ongoing study,
  • Known or suspected allergies or contraindications to aspirin and/or clopidogrel, heparin,
  • Coagulation disorders, or general refusal of the patient to receive blood transfusions,
  • Contrast allergy that cannot be treated,
  • Thrombolysis therapy including 72 hours before the planned index procedure,
  • Myocardial infarction or stroke <30 days prior to index procedure.
  • Equipment is unavailable to fulfill study treatments.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Interwoven stent

    Laser-cut stent

    Arm Description

    Use of an interwoven nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.

    Use of a laser-cut nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.

    Outcomes

    Primary Outcome Measures

    Primary patency
    Primary patency of the target lesion measured by duplex ultrasound

    Secondary Outcome Measures

    Changes in arterial flow within the target lesion
    Changes in blood flow/hemodynamics caused by the different stent designs measured by Computational Fluid Dynamics

    Full Information

    First Posted
    January 4, 2021
    Last Updated
    March 7, 2023
    Sponsor
    Kantonsspital Aarau
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04700371
    Brief Title
    Vessel Deformations and Restenosis After Stenting of the Popliteal Artery
    Acronym
    FIRESTEP
    Official Title
    Flexion-Induced Vessel Deformations and Restenosis After Stenting of the Popliteal Artery
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    December 1, 2023 (Anticipated)
    Primary Completion Date
    August 1, 2024 (Anticipated)
    Study Completion Date
    August 1, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Kantonsspital Aarau

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The femoro-popliteal (FP) artery is the most frequently treated vascular segment in patients with symptomatic peripheral artery disease (PAD), for which endovascular therapy became an established treatment option during the last decades. However, loss of primary patency and consecutive clinically driven target lesion revascularization (TLR) limit this procedure. Moreover, in the popliteal artery (PA), evidence about the best treatment strategy to prevent loss of patency and TLR is limited to only a few randomized controlled trials (RCT). Arterial deformations of the PA with its unique anatomical properties during leg flexion might explain the poor technical and clinical outcomes in this segment. Generally, a "leave nothing behind" strategy in the PA is preferred, but cannot be avoided in all cases due to e.g. flow limiting dissections or re-coil after balloon angioplasty. Basically two different self-expandable nitinol-based stent designs are available on the market. An interwoven nitinol and laser-cut nitinol stent. The interwoven nitinol stent has a higher radial force in comparison to the laser-cut stent and reveals higher patency rates in the FP arteries. However, a head-to-head comparison of these stents is missing and it remains unknown in which way different stent designs affect the deformation and hemodynamic behaviors of the PA during knee flexion.
    Detailed Description
    Randomized trial to investigate the impact of different stent designs on the target lesion restenosis rate in femoro-popliteal arteries. Immediately after stent implantation, sets of three orthogonal angiographic views (separated by an angle of > 25°) of the stented region (TL) will be obtained with the leg in supine position. This will be followed by intra-arterial imaging using Optical Coherence Tomography (OCT). OCT images (one pullback if the lesion length is < 75 mm, 2 pullbacks otherwise) of the TL will be acquired using the Dragonfly catheter. In addition, duplex ultrasound (DU) of the TL will be performed, including the arterial segments 10cm at proximal and distal edge of the TL. Thereafter, a bending cast will be used to obtain a knee/hip flexion of approximately 70°/20°. In this position the angiographic, OCT, and DU measurements will be repeated. The OCT images will provide the shapes of the arterial lumen which will be used to generate 3D surface models (in .stl format). The X-ray images will be utilized to construct the 3D arterial centerline for the supine and flexed leg positions. These arterial centerlines will be used to quantify the axial deformation (in mm), twisting (in °), and curvature changes (in mm-1) along the length of the investigated segment. Additionally, the lumen profiles obtained from OCT images will be used to accurately estimate the radial deformations (in mm) in the lumen and define instances of arterial pinching during leg flexion (as the difference in lumen diameters between straight and flexed leg positions). The geometries of the arterial lumens will be combined with their corresponding 3D arterial centerlines to generate patient-specific arterial models. Along with patient-specific boundary conditions obtained from DU measurements, these models will be transferred to a commercial software, to perform Computational Fluid Dynamics analyses. The changes in these parameters due to leg flexion, as well as due to different stent designs, will be quantified.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Peripheral Arterial Disease, Popliteal Artery Stenosis

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    110 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Interwoven stent
    Arm Type
    Active Comparator
    Arm Description
    Use of an interwoven nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
    Arm Title
    Laser-cut stent
    Arm Type
    Active Comparator
    Arm Description
    Use of a laser-cut nitinol stent to treat patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
    Intervention Type
    Device
    Intervention Name(s)
    Interwoven stent
    Intervention Description
    Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
    Intervention Type
    Device
    Intervention Name(s)
    Laser-cut stent
    Intervention Description
    Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
    Primary Outcome Measure Information:
    Title
    Primary patency
    Description
    Primary patency of the target lesion measured by duplex ultrasound
    Time Frame
    1 year post index procedure
    Secondary Outcome Measure Information:
    Title
    Changes in arterial flow within the target lesion
    Description
    Changes in blood flow/hemodynamics caused by the different stent designs measured by Computational Fluid Dynamics
    Time Frame
    6 weeks, 6 months, and 1 year post index procedure

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Written informed consent prior to any study procedure, Presence of PAD (2 - 3 Rutherford-Becker class), Atherosclerotic de-novo lesion (stenosis >70% or occlusion) of the distal part of the superficial femoral artery and/or any part of the popliteal artery, Target lesion-length: 4cm to 12cm, Target vessel diameter: 5mm to 7mm, Guidewire must cross target lesion and located intraluminally before randomization, At least one (1) patent below-the knee artery (=with no stenosis >50%), Possibility to treat the target lesion with one (1) study stent Interventions in TASC A and B lesions to restore adequate blood flow, in the same index procedure, are allowed. This intervention must be prior to the treatment of the study lesion(s) and successful. Exclusion Criteria: Pregnancy, Angiographic evidence of thrombus within the target lesion, Patients with acute critical limb ischemia (Rutherford-Becker class 4-6), Restenosis of the target lesion, Non-atherosclerotic obstructions of the target lesion, Aneurysm of the target lesion, Renal failure, defined as GFR, <40 mL/min/1.73m2, Patient's inability to follow the study procedures e.g. psychological disorders, dementia, etc., Previous enrolment into an ongoing study, Known or suspected allergies or contraindications to aspirin and/or clopidogrel, heparin, Coagulation disorders, or general refusal of the patient to receive blood transfusions, Contrast allergy that cannot be treated, Thrombolysis therapy including 72 hours before the planned index procedure, Myocardial infarction or stroke <30 days prior to index procedure. Equipment is unavailable to fulfill study treatments.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Aljoscha Rastan
    Phone
    0041628386458
    Email
    aljoscha.rastan@ksa.ch
    First Name & Middle Initial & Last Name or Official Title & Degree
    Christoph Thalhammer
    Phone
    0041628384703
    Email
    christoph.thalhammer@ksa.ch
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Aljoscha Rastan
    Organizational Affiliation
    Kantonsspital Aarau
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Vessel Deformations and Restenosis After Stenting of the Popliteal Artery

    We'll reach out to this number within 24 hrs